Cim LLC Acquires New Holdings in ADMA Biologics Inc $ADMA

Cim LLC bought a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 90,821 shares of the biotechnology company’s stock, valued at approximately $1,654,000.

Other hedge funds also recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $35,000. Cullen Frost Bankers Inc. increased its holdings in ADMA Biologics by 112.5% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares during the last quarter. Smartleaf Asset Management LLC raised its position in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,493 shares during the period. Ameritas Advisory Services LLC purchased a new stake in ADMA Biologics in the second quarter valued at approximately $46,000. Finally, Toth Financial Advisory Corp lifted its stake in ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 2,293 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Stock Down 2.9%

ADMA Biologics stock opened at $19.78 on Friday. The firm has a market capitalization of $4.71 billion, a P/E ratio of 23.00 and a beta of 0.43. The company has a current ratio of 7.13, a quick ratio of 3.65 and a debt-to-equity ratio of 0.18. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The stock’s fifty day simple moving average is $16.47 and its 200-day simple moving average is $17.26.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.15 earnings per share. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.